MGMT and central nervous system cancer: The tumoral IDH1 mutations are now known to confer favorable prognosis with longer progression-free survival (PFS) and its mutated form in glioma patients (WHO grade III) sees a median prognosis of approximately 3.5 versus approximately 1.5 years for wild-type gliomas [24,26,27], while patients with MGMT promoter methylation benefit from chemotherapy and show superior prognosis [28–31].